Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
about
Mutational profiling of kinases in glioblastoma.Imatinib mesylate for gastrointestinal stromal tumours (GISTs)Imatinib mesylate for gastrointestinal stromal tumours (GISTs)Imatinib mesylate for gastrointestinal stromal tumours (GISTs)Imatinib mesylate for gastrointestinal stromal tumours (GISTs)Imatinib mesylate for gastrointestinal stromal tumours (GISTs)Combined surgical and molecular therapy: the gastrointestinal stromal tumor modelStructural reengineering of imatinib to decrease cardiac risk in cancer therapyHighly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomasGenetic alteration and mutation profiling of circulating cell-free tumor DNA (cfDNA) for diagnosis and targeted therapy of gastrointestinal stromal tumorsTargeted therapy of gastrointestinal stromal tumoursSomatic DNA mutation analysis in targeted therapy of solid tumoursMore than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future HoldsEmerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future DirectionsThe GIST of targeted therapy for malignant melanomaMoving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial designPersonalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistanceClinical practice guidelines for patients with gastrointestinal stromal tumor in TaiwanKIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patientsPrimary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumorThe outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.Unveiling changes in the landscape of patient populations in cancer early drug developmentAdvanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendationsPazopanib, a new therapy for metastatic soft tissue sarcomaCurrent management and prognostic features for gastrointestinal stromal tumor (GIST)Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancersRole of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profilesKey messages from the BFR14 trial of the French Sarcoma Group.Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial.Strategies for modern biomarker and drug development in oncology.Discovering Outliers of Potential Drug Toxicities Using a Large-scale Data-driven ApproachImatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.[Hemato-oncological diseases].Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumorsGastrointestinal stromal tumor.Detection of treatment-induced changes in signaling pathways in gastrointestinal stromal tumors using transcriptomic data.
P2860
Q21261249-28A6BF73-1217-41B4-8147-5AF8A24CD252Q24200254-75F04EEC-2E4C-4492-A71A-73D4E6DD150FQ24234239-715C0E9B-9504-480D-9448-43290D96AC3AQ24234579-701820D1-893F-4030-81F4-A1A18E0F32B4Q24235034-C79E1174-0467-4C4C-91D3-BEDD51759FA3Q24240660-197A3F0C-FA19-4936-8AD8-995F5FF347DCQ24675987-FD02F2F3-305D-4A1E-80E8-1B8B39BC9E32Q24685557-D906C140-AA5B-4D0A-B9A8-FB810DC4CF79Q24685605-A78334E8-AF97-4180-8909-57ABB594E8C6Q26738567-C0E00CBF-C894-4EAB-86A1-2298EF5BBE4BQ26745633-74B1C70B-68E8-42D6-8B58-F9E368DA504BQ26770324-EA794B74-D52A-41A5-8B1B-A60F5D988D20Q26781662-A36C53C6-EEFE-4EC3-B02C-F1F83E3AE8BFQ26799387-1F8CA7CC-04DD-4835-9183-C18EE4317CAAQ26827092-4E7F4C3C-CF4F-46F6-84BA-8D0FB5E42A46Q26830525-D0888BE0-8B02-4A23-BE96-C4F1985622FDQ26866517-65621051-3724-4AC8-91B7-249EDB19A388Q27027632-FF3FC573-9BAE-4B24-B27E-457AC41BD27CQ27653496-F4A40BE5-0ABC-4A28-8771-F5FDE7677006Q27851455-5FCB5FEE-1FEE-42FE-BA2D-7294472D03F1Q27851744-AA182504-C341-46FA-AFF1-EE0E28046053Q27853181-9439F207-1101-47AB-B648-C7A724A121CBQ28073826-472DD938-1850-41E0-858F-C110013044EDQ28247449-7B1ECC1B-CBCE-4591-8E79-E040BE2313EBQ28287163-DE347215-90BF-44F0-9C04-58F1C1F768FAQ28391684-EF329054-2EDE-4331-A75B-F6CBAA6A3444Q28484970-89FF8918-F928-4B07-B158-78955A5AB2F4Q28765146-454A5C8D-FF6C-4898-8392-5CBD224C3CD0Q29617464-6859142E-4080-420F-B694-806F69B550B3Q30245384-817B2CD7-55FC-464F-8ADF-53C9128E790BQ30245586-08151F5D-9922-4940-864D-76E33F5C87DEQ30485073-DE7CB219-1965-4612-A00C-81F8E868D531Q30590270-659AF620-63F4-4346-B578-C385DB6CAFAAQ31140868-32623B2F-D08E-4C3F-A569-9DF84AA1E400Q33390293-2FD40806-2A4C-46D2-BEA7-8880BA98F7FEQ33392955-29E46072-533A-4FE1-9E71-722E59710945Q33410075-65AB549F-55E0-4620-9FE5-8FB8DE448047Q33412724-C2E77188-2A23-4FA1-82E7-C6A5FBB94887Q33489084-2248D1DB-4F0A-4675-9053-9252FB769910Q33515723-9B0D628C-A328-4F74-8494-1CB21E03A257
P2860
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Progression-free survival in g ...... se imatinib: randomised trial.
@ast
Progression-free survival in g ...... se imatinib: randomised trial.
@en
Progression-free survival in g ...... se imatinib: randomised trial.
@nl
type
label
Progression-free survival in g ...... se imatinib: randomised trial.
@ast
Progression-free survival in g ...... se imatinib: randomised trial.
@en
Progression-free survival in g ...... se imatinib: randomised trial.
@nl
prefLabel
Progression-free survival in g ...... se imatinib: randomised trial.
@ast
Progression-free survival in g ...... se imatinib: randomised trial.
@en
Progression-free survival in g ...... se imatinib: randomised trial.
@nl
P2093
P50
P1433
P1476
Progression-free survival in g ...... se imatinib: randomised trial.
@en
P2093
Allan van Oosterom
Axel LeCesne
Ian Judson
Jaap Verweij
John Zalcberg
Martine Van Glabbeke
Pancras C W Hogendoorn
Peter Reichardt
Rolf Issels
P304
P356
10.1016/S0140-6736(04)17098-0
P407
P577
2004-09-01T00:00:00Z